EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort

Christine Højte, Mette Frahm Olsen, Daniel Faurholt-Jepsen, Marianne Hørby Jørgensen, Tacjana Pressler, Christian Leo-Hansen, Thomas Bryrup, Majbritt Jeppesen, Hanne Vebert Olesen, Janne Petersen, Terese L Katzenstein, Bibi Uhre Nielsen und 2 weitere

Journal of Cystic Fibrosis · 2025

DOI: 10.1016/j.jcf.2025.08.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Christine Højte und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Danish Cystic Fibrosis Cohort, Denmark; Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Denmark; Department o…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Chemical and Drug Induced Liver Injury, Benzodioxoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Copenhagen University Hospital Rigshospitalet, Vertex Pharmaceuticals Incorporated.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Elexacaftor/Tezacaftor/Ivacaftor (ETI) has raised concerns about liver-related side effects. This study evaluated changes in liver function tests (LFTs) and the prevalence of hepatotoxicity over two years of ETI treatment in a nationwide cohort of Danish people with cystic fibrosis (pwCF) METHODS: Changes in LFTs were assessed in pwCF aged ≥12 years, including those with pre-existing hepatic impairment, using data from the Danish CF Registry (2016-2025). Statistical analyses included piecewise linear mixed models for long-term changes and descriptive analysis of abnormal LFTs to assess hepatotoxicity. RESULTS: A total of 331 pwCF were included. Compared to pre-ETI levels, alanine aminotransferase (ALT) levels were significantly elevated at six months post-ETI but stabilized and approached pre-ETI levels by 24 months. Alkaline phosphatase (ALP) levels were lower at all timepoints, with a statistically significant decrease at 24 months. Gamma-glutamyl transferase (GGT) levels were consistently lower post-ETI. The prevalence of abnormal ALT, ALP, and GGT was initially higher post-ETI, peaking at one month, then steadily declining to pre-treatment values within two years. Three individuals (0.9 %) had signs of severe hepatotoxicity with ALT >5x upper limit of normal (ULN) and bilirubin >2xULN post-ETI. Among those with pre-existing hepatic impairment and those with unexpected liver complications post-ETI 5/7 and 5/8, respectively, reached the full ETI dose. CONCLUSION: ALT levels almost normalized, while GGT and ALP levels declined within two years of ETI treatment. Reassuringly, severe hepatotoxicity was rare, suggesting that close monitoring may suffice for managing mild to moderate hepatotoxicity in pwCF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsChemical and Drug Induced Liver InjuryBenzodioxolesQuinolonesIndolesPyrazolesPyrrolidinesPyridinesHumansMaleFemaleDenmarkLiver Function TestsDrug CombinationsAdultFollow-Up StudiesChloride Channel AgonistsAdolescentYoung AdultRegistries

Stichwörter der Autor:innen

Cystic fibrosis liver diseaseElexacaftor/Tezacaftor/IvacaftorHepatotoxicityLong-term changes

Substanzen

AminophenolsBenzodioxolesDrug CombinationsQuinolonesIndolesChloride Channel AgonistsPyrazolesPyrrolidinesPyridines

Autor:innen und Institutionen

  • The Danish Cystic Fibrosis Cohort, Denmark; Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Denmark; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital -…
  • The Danish Cystic Fibrosis Cohort, Denmark; Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Denmark; Department of Nutrition, Exercise and Sports, University of Copenhagen, Denmark.
  • The Danish Cystic Fibrosis Cohort, Denmark; Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.
  • Department of Pediatric Gastroenterology, Copenhagen University Hospital - Rigshospitalet, Denmark.
  • The Danish Cystic Fibrosis Cohort, Denmark; Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet, Denmark.
  • The Danish Cystic Fibrosis Cohort, Denmark; Department of Infectious Diseases, Aarhus University Hospital, Denmark.

Förderung

  • Copenhagen University Hospital Rigshospitalet
  • Vertex Pharmaceuticals Incorporated

Zitieren

APA

Højte, C., Olsen, M. F., Faurholt-Jepsen, D., Jørgensen, M. H., Pressler, T., Leo-Hansen, C., Bryrup, T., Jeppesen, M., Olesen, H. V., Petersen, J., Katzenstein, T. L., Nielsen, B. U., Skov, M., & TransformCF Study Group (2025). Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.08.008

Vancouver

Højte C, Olsen MF, Faurholt-Jepsen D, Jørgensen MH, Pressler T, Leo-Hansen C, et al. Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.08.008

BibTeX
@article{Hjte2025,
  author = {Højte, Christine and Olsen, Mette Frahm and Faurholt-Jepsen, Daniel and Jørgensen, Marianne Hørby and Pressler, Tacjana and Leo-Hansen, Christian and Bryrup, Thomas and Jeppesen, Majbritt and Olesen, Hanne Vebert and Petersen, Janne and Katzenstein, Terese L and Nielsen, Bibi Uhre and Skov, Marianne and TransformCF Study Group, TransformCF Study Group},
  title = {Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  doi = {10.1016/j.jcf.2025.08.008}
}
Kostenlos starten →